MedTrace Logo

Exposure and Response Prevention Therapy for Obsessive-compulsive Disorder

NCT02602886 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2016-11-29

No results posted yet for this study

Summary

The purpose of this research study is to evaluate whether Exposure and Response Prevention Therapy (ERP) can help adults with obsessive-compulsive disorder (OCD) in China following a training of professionals and ongoing consultation.

Conditions

  • Obsessive-Compulsive Disorder

Interventions

BEHAVIORAL

Exposure and Response Prevention Therapy

The treatment includes both therapist-supervised and self-controlled exposure and ritual prevention exercises. 2 sessions per week, up to 15 sessions in total. Session time is 90 minutes. The majority of in-session time is spent conducting in vivo exposures. When engaging in E/RP tasks, patients are instructed to refrain from ritual engagement. Between-session homework is given the patient practicing the within-session E/RP task up to 90 minutes each day. Clinicians supplement E/RP with other cognitive-behavioral interventions including motivational strategies for resistant patients, Socratic dialogue, and behavioral experiments to test the validity of erroneous cognitions.

Sponsors & Collaborators

  • Shanghai Hongkou Mental Health Center

    collaborator UNKNOWN

  • West China Hospital

    collaborator OTHER

  • Suzhou Guangji Hospital

    collaborator UNKNOWN

  • First Affiliated Hospital of Xinjiang Medical University

    collaborator OTHER

  • The SHSMU-ION Research Center for Brain Disorders

    collaborator UNKNOWN

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Bomin Sun, MD, PhD · Ruijin Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02602886 on ClinicalTrials.gov